Leerink Partnrs Issues Optimistic Forecast for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for shares of Axsome Therapeutics in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($1.21) per share for the quarter, up from their previous estimate of ($1.22). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($4.39) EPS, FY2027 earnings at $3.15 EPS, FY2028 earnings at $9.25 EPS and FY2029 earnings at $15.40 EPS.

AXSM has been the subject of several other research reports. Morgan Stanley upped their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 target price on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Jefferies Financial Group started coverage on Axsome Therapeutics in a research report on Monday, April 7th. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Bank of America boosted their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $172.14.

Axsome Therapeutics Stock Down 1.0 %

AXSM opened at $107.76 on Thursday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The business has a 50 day moving average price of $112.01 and a two-hundred day moving average price of $104.51. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The company has a market cap of $5.31 billion, a PE ratio of -17.99 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 22.30% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NBC Securities Inc. purchased a new position in shares of Axsome Therapeutics during the 1st quarter worth about $31,000. Neo Ivy Capital Management acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $41,000. Raiffeisen Bank International AG purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $51,000. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics during the 4th quarter worth $52,000. Finally, R Squared Ltd acquired a new position in Axsome Therapeutics in the fourth quarter valued at $64,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.